Generic Makers Flock to Samsca’s Heart Failure Market after Patent Invalidated; Gx Listing Expected in December

August 16, 2022
A host of companies on August 15 obtained generic approval for a 15 mg OD tablet version of Otsuka Pharmaceutical’s diuretic agent Samsca (tolvaptan), which is indicated for use in heart failure patients, after a relevant patent was invalidated in...read more